Announcement on behalf of OBIGEN of re-election of directors and supervisors at the 2024 Annual General Shareholders’ meeting

1.Date of occurrence of the change:2024/06/19
2.Elected or changed position (Please enter institutional
director, institutional supervisor, independent director,
natural-person director or natural-person supervisor):institutional director
and natural-person supervisor
3.Title and name of the previous position holder:
Director Frank Chen, Representative of OBI Pharma Inc.
Director Heidi Wang, Representative of OBI Pharma Inc.
Director Jo Ma, Representative of OBI Pharma Inc.
Director Hsing-Ming Chen, Representative of OBI Pharma Inc.
Director Chung Yao Yin, Representative of RuentexSin, Inc.
Supervisor Colin Kao
4.Resume of the previous position holder:
Director Frank Chen, Representative of OBI Pharma Inc./ Vice President,
Investment Management Department and Special Assistant to
President, Ruentex Group
Director Heidi Wang, Representative of OBI Pharma Inc./ Chief Executive
Officer, OBI Pharma Inc.
Director Jo Ma, Representative of OBI Pharma Inc./ Director of Formosa
Pharmaceuticals, Inc.
Director Hsing-Ming Chen, Representative of OBI Pharma Inc./ General
Manager, Intelligent-Bio Co., Ltd.
Director Chung Yao Yin, Representative of RuentexSin, Inc./ Chairperson,
Nan Shan Life Insurance Co., Ltd
Supervisor Colin Kao/ Finance director, OBI Pharma Inc.
5.Title and name of the new position holder:
Director Frank Chen, Representative of OBI Pharma Inc.
Director Heidi Wang, Representative of OBI Pharma Inc.
Director Jo Ma, Representative of OBI Pharma Inc.
Director Hsing-Ming Chen, Representative of OBI Pharma Inc.
Director Chung Yao Yin, Representative of RuentexSin, Inc.
Supervisor Colin Kao
Supervisor Wan-Fang Ting
6.Resume of the new position holder:
Director Frank Chen, Representative of OBI Pharma Inc./ Vice President,
Investment Management Department and Special Assistant to
President, Ruentex Group
Director Heidi Wang, Representative of OBI Pharma Inc./ Chief Executive
Officer, OBI Pharma Inc.
Director Jo Ma, Representative of OBI Pharma Inc./ Director of Formosa
Pharmaceuticals, Inc.
Director Hsing-Ming Chen, Representative of OBI Pharma Inc./ General
Manager, Intelligent-Bio Co., Ltd.
Director Chung Yao Yin, Representative of RuentexSin, Inc./ Chairperson,
Nan Shan Life Insurance Co., Ltd.
Supervisor Colin Kao/ Finance director, OBI Pharma Inc.
Supervisor Wan-Fang Ting/ Manager, Investment Management Department,
Ruentex Group
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):Term expired
8.Reason for the change:
Full re-election of directors and supervisors due to term expired
9.Number of shares held by the new position holder when elected:
Director Frank Chen, Representative of OBI Pharma Inc./ 55,062,500 shares
Director Heidi Wang, Representative of OBI Pharma Inc./ 55,062,500 shares
Director Jo Ma, Representative of OBI Pharma Inc./ 55,062,500 shares
Director Hsing-Ming Chen, Representative of OBI Pharma Inc./ 55,062,500
shares
Director Chung Yao Yin, Representative of RuentexSin, Inc./ 5,000,000
shares
Supervisor Colin Kao/ 81,250 shares
Supervisor Wan-Fang Ting/ 82,000 shares
10.Original term (from __________ to __________):From 2021/04/26 to 2024/04/25
11.Effective date of the new appointment:2024/06/19
12.Turnover rate of directors of the same term: Not applicable
13.Turnover rate of independent directors of the same term: Not applicable
14.Turnover rate of supervisors of the same term: Not applicable
15.Change in one-third or more of directors (Please enter “Yes” or
“No”): Not applicable
16.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.): None